New drug hope for deadly brain cancer: troriluzole tested before surgery

NCT ID NCT06552260

First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 29 times

Summary

This early-phase trial tests whether the drug troriluzole can affect brain activity and reduce harmful glutamate levels in people with recurrent glioblastoma, an aggressive brain cancer. About 27 adults whose tumor has returned after standard treatment will receive the drug before their scheduled surgery. Researchers will compare their brain signals and tumor tissue to those who did not get the drug, looking for signs that troriluzole may help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital Cancer Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.